Nautilus Biotechnolgy, Inc.
NAUT
NASDAQ·Healthcare·Biotechnology·Mkt cap $115.2M
$0.90
▼ -1.59%
P/E
-2.01
Mkt Cap
$115.2M
52-Wk Range
$0.65–$4.31
52-Week Range
$0.65 - $4.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 29.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary end-to-end proteomics platform technology
- Differentiated instrument design with integrated software capabilities
- Early-mover advantage in next-generation proteomics market
- Strategic partnerships with leading pharmaceutical and research institutions
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Increasing adoption of proteomics in pharmaceutical drug discovery and development
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-61.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NAUT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of -$0.11 vs -$0.14 consensus (+18.5% surprise). Revenue of $190.0K vs $100.0K expected (+90.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+18.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$190.0K
Margins · last 8Q
Profit
-7615.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How NAUT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.